Last reviewed · How we verify
Oral Insulin
At a glance
| Generic name | Oral Insulin |
|---|---|
| Sponsor | Technical University of Munich |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial (NA)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Polycystic Ovary Syndrome in Type 1 Diabetes
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (PHASE1)
- Effects of Cofrogliptin on Beta-Cell Function in LADA Patients (NA)
- Cistanche Deserticola Extract Combined With Aerobic Exercise Improves Body Composition, Insulin Resistance and Inflammation in Men With Central Obesity (NA)
- Study for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Insulin CI brief — competitive landscape report
- Oral Insulin updates RSS · CI watch RSS
- Technical University of Munich portfolio CI